NASDAQ · Biotechnology

UroGen Pharma Ltd. (URGN) Stock

$40.81 -0.39% NASDAQ: URGN Healthcare

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.

Valuation

MetricValue
Price$40.81
Market Cap$1.99B
P/E Ratio-14.90
P/B Ratio-16.55
P/S Ratio14.21
EPS (TTM)$-3.19
52-Week High$43.93
52-Week Low$15.86
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE121.52%
ROA-52.51%
ROCE-53.29%
Gross Margin89.85%
Operating Margin-77.02%
Net Margin-94.83%
Debt/Equity-1.59
Current Ratio4.04

Annual Financials (USD)

Metric20212022202320242025
Revenue$48.0M$64.0M$83.0M$90.0M$110.0M
Operating Profit$-92.0M$-79.0M$-66.0M$-97.0M$-125.0M
Net Profit$-111.0M$-110.0M$-102.0M$-127.0M$-153.0M
EPS$-4.96$-4.79$-3.55$-2.96$-3.19
Op Margin-192.1%-122.8%-79.2%-107.1%-113.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$120.0M$136.0M$178.0M$286.0M$200.0M
Total Liabilities$111.0M$225.0M$244.0M$295.0M$306.0M
Cash$44.0M$55.0M$95.0M$172.0M$111.0M
Borrowings$0$99.0M$99.0M$123.0M$128.0M

Latest News

Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks · Jul 30, 2026 UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026 GlobeNewswire · Jul 29, 2026 Why Did CVS, URGN, CCK Stocks Hit 52-Week Highs Today? Stocktwits · Jul 22, 2026 Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027 Barchart · Jul 17, 2026 Oppenheimer Adjusts Price Target on UroGen Pharma to $50 From $40, Maintains Outperform Rating MT Newswires · Jul 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-85.0M$-88.0M$-76.0M$-97.0M$-162.0M
Investing Cash Flow$3.0M$1.0M$-1.0M$-21.0M$61.0M
Financing Cash Flow$72.0M$0$50.0M$19.0M$0
Net Cash Flow$-9.0M$11.0M$40.0M$77.0M$-61.0M
Free Cash Flow$-86.0M$-88.0M$-77.0M$-97.0M$-163.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.23
EV / EBITDA-18.19
FCF Yield-8.20%
Quick Ratio3.70
Interest Coverage-3.68
Return 1Y148.00%
Return 3Y352.74%
Return 5Y174.90%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANAB $53.61 -1.00% -127.70 $2.31B 0.00%
BBOT $8.09 -4.82% -3.62 $648.07M 0.00%
KOD $41.58 -2.16% -8.11 $2.60B 0.00%
MNMDMind Medicine (MindMed) Inc. $20.69 +0.44% -18.83 $1.56B 0.00%
NRIX $24.11 -0.17% -6.41 $2.50B 0.00%

About UroGen Pharma Ltd.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

UroGen Pharma Ltd. is led by CEO Elizabeth A. Barrett, employs 234 people, headquartered in US, publicly traded since 2017.

UroGen Pharma Ltd. (URGN) stock trades at $40.81 with a market capitalization of $1.99B. The stock is valued at a price-to-earnings (P/E) ratio of -14.90, price-to-book of -16.55, price-to-sales of 14.21. Over the past 52 weeks the stock has ranged between $15.86 and $43.93, and currently trades 7.1% below its 52-week high.

On profitability, UroGen Pharma Ltd. generates a return on equity (ROE) of 121.52% — well above the market average, a sign of a high-quality business, return on capital employed of -53.29%, an operating margin of -77.02%, a net profit margin of -94.83%.

Official website: www.urogen.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides